Form 4: CARLSMED CEO Michael Cordonnier Reports Significant Stock Option Grant and Preferred Stock Conversion

CARLSMED, Inc. CEO and President Michael Cordonnier reported the acquisition of 142,857 stock options and the conversion of 3,612 shares of Series B Preferred Stock into common stock.

Summary

• Michael Cordonnier, CEO and President of CARLSMED, Inc., reported transactions on July 22, 2025, and July 24, 2025.
• On July 22, 2025, Cordonnier was granted 142,857 stock options with an exercise price of $15 per share, which are set to expire on July 9, 2035.
• These stock options will vest in equal quarterly installments over four years, commencing from the grant date of July 22, 2025, provided Cordonnier remains in continuous service.
• On July 24, 2025, 3,612 shares of Series B Preferred Stock were converted into an equal number of common stock shares immediately prior to the company's initial public offering (IPO) without additional consideration.
• Following these reported transactions, Cordonnier directly beneficially owns 1,239,330 shares of common stock and 726,235 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports a significant stock option grant to the CEO, which is generally positive as it aligns management incentives with long-term shareholder value. The preferred stock conversion is a standard capital structure adjustment, likely related to an IPO, and is neutral to positive.

Positives

• The grant of 142,857 stock options to the CEO aligns management incentives with long-term shareholder interests.
• The conversion of preferred stock to common stock simplifies the capital structure, which is a positive step, especially in anticipation of or immediately following an IPO.

Future Outlook

The granted stock options will begin to vest in equal installments on each quarterly anniversary of July 22, 2025, with full vesting on the fourth anniversary of the grant date, contingent on Michael Cordonnier's continuous service.

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's interests with shareholders through equity compensation.
• Shareholders: Simplification of the capital structure due to preferred stock conversion.

Next Steps

• Continued vesting of 142,857 stock options over the next four years, contingent on Michael Cordonnier's continuous service.

Key Dates

Recommendation

This Form 4 filing primarily reports routine insider transactions related to executive compensation and capital structure adjustments around an IPO. While the stock option grant aligns the CEO's interests with shareholders, it does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a 'buy' or 'sell' recommendation. It is a standard disclosure for an executive's equity holdings.

Keywords

CARLSMED, CARL, Michael Cordonnier, SEC Form 4, Insider Transaction, Stock Options, Preferred Stock Conversion, CEO, Director, Equity Compensation, IPO